Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8007)	3/12/2003 3:46:00 PM
From: Robohogs	Read Replies (1) \| Respond to of 52153

Any feel for the impact of this KG action on the Elan drug deal (Sonata + one)? Thanks. Jon

To: Biomaven who wrote (8007)	3/12/2003 3:47:39 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

I note that Forest labs now is the biggest player in New antidepressant prescriptions, with 22.7% of the market, split between Celexa (12.6% and falling) and Lexapro (10.2% and rising sharply). The runner-up is PFE with Zoloft's 22%. For Total Rx's, Zoloft still leads by about 1.6%. Turning to another biotech with strong fundamentals, I note that two big brokers have just upped GILD's estimated 2004 earnings. We haven't talked much about GILD, but it's worth noticing that they are one of the few biotechs to have successfully bought more than one small molecule drug all the way to market. What is more, I think Viread, Tamiflu and Hepsera are each best-in-class. A potential Viread/FTC once-a-day combo pill seems to me to be set to become a standard of care, likely with Sustiva as the other drug. Merrill estimates that Viread and the Viread/FTC combo could be a billion dollar seller by 2007. (Viread is currently a $225m drug). Most of my GILD position is currently in the form of some near-term calls, but I'm thinking that I'll exercise and hold part of the calls. Peter